Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway-Reference-Cited by-同舟云学术

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

Published:2009-07 Issue:4 Volume:10 Page:281-289
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Nguyen Kim-Son H.,Kobayashi Susumu,Costa Daniel B.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference94 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

4. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

5. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

Cited by 381 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BMS345541 is predicted as a repurposed drug for the treatment of TMZ-resistant Glioblastoma using target gene expression and virtual drug screening;Cancer Genetics;2024-11

2. Design, synthesis and anticancer activity of β-carboline based pseudo-natural products by inhibiting AKT/mTOR signaling pathway;Bioorganic Chemistry;2024-10

3. PCK2 induces gefitinib resistance by suppresses ferroptosis in non-small cell lung cancer;Biochemical and Biophysical Research Communications;2024-09

4. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy;Medicine in Drug Discovery;2024-09

5. Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancer;Bioorganic & Medicinal Chemistry;2024-09